Charting γ-secretase substrates by explainable AI.

Journal: Nature communications
Published Date:

Abstract

Proteases recognize substrates by decoding sequence information-an essential cellular process elusive when recognition motifs are absent. Here, we unravel this problem for γ-secretase, an intramembrane-cleaving protease associated with Alzheimer's disease and cancer, by developing Comparative Physicochemical Profiling (CPP), a sequence-based algorithm for identifying interpretable physicochemical features. We show that CPP deciphers a γ-secretase substrate signature with single-residue resolution, which can explain the conformational transitions observed in substrates upon γ-secretase binding. Using machine learning, we predict the entire human γ-secretase substrate scope, revealing numerous previously unknown substrates. Our approach outperforms state-of-the-art protein language models, improving prediction accuracy from 60% to 90%, and achieves an 88% success rate in experimental validation. Building on these advancements, we identify pathways and diseases not linked before to γ-secretase. Generally, CPP decodes physicochemical signatures-a concept that extends beyond sequence motifs. We anticipate that our approach will be broadly applicable to diverse molecular recognition processes.

Authors

  • Stephan Breimann
    Department of Bioinformatics, School of Life Sciences, Technical University of Munich, Freising, Germany; Ludwig-Maximilians-University Munich, Biomedical Center, Division of Metabolic Biochemistry, Munich, Germany; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
  • Frits Kamp
    Ludwig-Maximilians-University Munich, Biomedical Center, Division of Metabolic Biochemistry, Munich, Germany.
  • Gabriele Basset
    Biomedical Center (BMC), Division of Metabolic Biochemistry, Faculty of Medicine, LMU Munich, München, Germany.
  • Claudia Abou-Ajram
    Biomedical Center (BMC), Division of Metabolic Biochemistry, Faculty of Medicine, LMU Munich, München, Germany.
  • Gökhan Güner
    German Center for Neurodegenerative Diseases (DZNE), DZNE Munich, München, Germany.
  • Kanta Yanagida
    Department of Pharmacotherapeutics II, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
  • Masayasu Okochi
    Neuropsychiatry, Department of Integrated Medicine, Division of Internal Medicine, Osaka University Graduate School of Medicine, Suita, Japan.
  • Stephan A Müller
    German Center for Neurodegenerative Diseases (DZNE), DZNE Munich, München, Germany.
  • Stefan F Lichtenthaler
    German Center for Neurodegenerative Diseases (DZNE), DZNE Munich, München, Germany.
  • Dieter Langosch
    Biopolymer Chemistry, TUM, Freising, Germany.
  • Dmitrij Frishman
    Department of Bioinformatics, Technische Universität München, Wissenschaftszentrum Weihenstephan, Freising, Germany.
  • Harald Steiner
    Ludwig-Maximilians-University Munich, Biomedical Center, Division of Metabolic Biochemistry, Munich, Germany; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.